PLoS ONE (Jan 2019)

Mindfulness-Based Blood Pressure Reduction (MB-BP): Stage 1 single-arm clinical trial.

  • Eric B Loucks,
  • William R Nardi,
  • Roee Gutman,
  • Ian M Kronish,
  • Frances B Saadeh,
  • Yu Li,
  • Anna E Wentz,
  • Julie Webb,
  • David R Vago,
  • Abigail Harrison,
  • Willoughby B Britton

DOI
https://doi.org/10.1371/journal.pone.0223095
Journal volume & issue
Vol. 14, no. 11
p. e0223095

Abstract

Read online

Background and objectivesImpacts of mindfulness-based programs on blood pressure remain equivocal, possibly because the programs are not adapted to engage with determinants of hypertension, or due to floor effects. Primary objectives were to create a customized Mindfulness-Based Blood Pressure Reduction (MB-BP) program, and to evaluate acceptability, feasibility, and effects on hypothesized proximal self-regulation mechanisms. Secondary outcomes included modifiable determinants of blood pressure (BP), and clinic-assessed systolic blood pressure (SBP).MethodsThis was a Stage 1 single-arm trial with one year follow-up. Focus groups and in-depth interviews were performed to evaluate acceptability and feasibility. Self-regulation outcomes, and determinants of BP, were assessed using validated questionnaires or objective assessments. The MB-BP curriculum was adapted from Mindfulness-Based Stress Reduction to direct participants' mindfulness skills towards modifiable determinants of blood pressure.ResultsAcceptability and feasibility findings showed that of 53 eligible participants, 48 enrolled (91%). Of these, 43 (90%) attended at least 7 of the 10 MB-BP classes; 43 were followed to one year (90%). Focus groups (n = 19) and semi-structured interviews (n = 10) showed all participants viewed the delivery modality favorably, and identified logistic considerations concerning program access as barriers. A priori selected primary self-regulation outcomes showed improvements at one-year follow-up vs. baseline, including attention control (Sustained Attention to Response Task correct no-go score, pConclusionMB-BP has good acceptability and feasibility, and may engage with self-regulation and behavioral determinants of hypertension.